CTOs on the Move

T Ray Science

www.t-rayscience.com

 
Company ProfileVerisante Technology, Inc (Formerly T-Ray Science) is a medical device company committed to developing innovative systems for the early detection of cancer.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Girling Health Care

The Girling Difference Girling Health Care of NY is a leading provider of home health and home concierge care services. We provide personalized, professional care for patients in the comfort of their homes. Our services include home companions, skilled...

Neopharm Labs

As a trusted partner to leaders in the pharmaceutical and life sciences industry for over 30 years, we`ve built a reputation for quality, problem‑solving capabilities, and a superior customer experience. We`re proud to play an integral role in bettering the lives of the global community.

Allarity Therapeutics

Allarity Therapeutics (Nasdaq: ALLR) is a clinical-stage precision medicine company actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. The company is leveraging its proprietary, highly accurate Drug Response Predictor (DRP®) technology to refine patient selection and improve clinical outcomes. Publicly traded on NASDAQ, Allarity (ALLR) is headquartered in Cambridge, MA, while maintaining an R&D facility in Hoersholm, Denmark. Allarity is committed to enhancing patient outcomes through improved decision-making and personalized cancer care.

Ingles Market

Ingles Market, Inc. is a Albemarle, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BrainStorm Cell

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn® has been administered to over 50 patients with ALS in clinical trials conducted in Israel and the United States, and is currently being studied in a randomized, double-blind, placebo-controlled clinical trial in the United States.